{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}],"groups":[{"description":"Ixazomib 0.24 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).","id":"BG000","title":"Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2"},{"description":"Ixazomib 0.48 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).","id":"BG001","title":"Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2"},{"description":"Ixazomib 0.8 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).","id":"BG002","title":"Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2"},{"description":"Ixazomib 1.2 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).","id":"BG003","title":"Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2"},{"description":"Ixazomib 1.68 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).","id":"BG004","title":"Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).","id":"BG005","title":"Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2"},{"description":"Ixazomib 2.23 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).","id":"BG006","title":"Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).","id":"BG007","title":"Relapsed and Refractory Expansion Cohort: Ixazomib 2.0 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \\>=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).","id":"BG008","title":"Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \\>=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).","id":"BG009","title":"Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).","id":"BG010","title":"Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2"},{"description":"Total of all reporting groups","id":"BG011","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.02","value":"65.3"},{"groupId":"BG001","spread":"6.81","value":"61.3"},{"groupId":"BG002","spread":"12.10","value":"69.3"},{"groupId":"BG003","spread":"7.00","value":"66.0"},{"groupId":"BG004","spread":"9.85","value":"64.0"},{"comment":"Standard deviation is not estimable for 1 participant.","groupId":"BG005","spread":"NA","value":"78"},{"groupId":"BG006","spread":"7.50","value":"64.3"},{"groupId":"BG007","spread":"9.58","value":"64.4"},{"groupId":"BG008","spread":"8.02","value":"65.4"},{"groupId":"BG009","spread":"6.84","value":"64.0"},{"groupId":"BG010","spread":"3.54","value":"71.5"},{"groupId":"BG011","spread":"8.25","value":"65.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"28"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"32"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"55"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"18"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"54"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"5"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.63","value":"173.1"},{"groupId":"BG001","spread":"7.60","value":"167.5"},{"groupId":"BG002","spread":"4.54","value":"167.4"},{"groupId":"BG003","spread":"14.25","value":"180.1"},{"groupId":"BG004","spread":"7.90","value":"165.4"},{"comment":"Standard deviation is not estimable for 1 participant.","groupId":"BG005","spread":"NA","value":"178"},{"groupId":"BG006","spread":"12.18","value":"169.7"},{"groupId":"BG007","spread":"11.28","value":"165.8"},{"groupId":"BG008","spread":"13.26","value":"165.7"},{"groupId":"BG009","spread":"9.16","value":"169.3"},{"groupId":"BG010","spread":"6.08","value":"156.7"},{"groupId":"BG011","spread":"11.07","value":"167.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"59"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Here, number analyzed are the participants who were evaluated for this baseline measure.","title":"Height","unitOfMeasure":"centimeter (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.560","value":"87.50"},{"groupId":"BG001","spread":"5.937","value":"71.03"},{"groupId":"BG002","spread":"5.036","value":"74.87"},{"groupId":"BG003","spread":"12.760","value":"109.90"},{"groupId":"BG004","spread":"2.542","value":"80.77"},{"comment":"Standard deviation is not estimable for 1 participant.","groupId":"BG005","spread":"NA","value":"82.3"},{"groupId":"BG006","spread":"21.532","value":"82.98"},{"groupId":"BG007","spread":"23.760","value":"77.81"},{"groupId":"BG008","spread":"15.579","value":"72.60"},{"groupId":"BG009","spread":"16.811","value":"93.20"},{"groupId":"BG010","spread":"36.770","value":"71.70"},{"groupId":"BG011","spread":"19.946","value":"80.27"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kilogram (kg)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.192","value":"2.05"},{"groupId":"BG001","spread":"0.100","value":"1.82"},{"groupId":"BG002","spread":"0.062","value":"1.86"},{"groupId":"BG003","spread":"0.229","value":"2.34"},{"groupId":"BG004","spread":"0.071","value":"1.93"},{"comment":"Standard deviation is not estimable for 1 participant.","groupId":"BG005","spread":"NA","value":"2.02"},{"groupId":"BG006","spread":"0.335","value":"1.97"},{"groupId":"BG007","spread":"0.342","value":"1.88"},{"groupId":"BG008","spread":"0.237","value":"1.82"},{"groupId":"BG009","spread":"0.265","value":"2.09"},{"groupId":"BG010","spread":"0.495","value":"1.74"},{"groupId":"BG011","spread":"0.291","value":"1.92"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"59"}],"units":"Participants"}]}],"description":"Body Surface Area (m\\^2)=\\[Height(cm) \\* Weight (kg)\\]/3600)\\^1/2.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Here, number analyzed are the participants who were evaluated for this baseline measure.","title":"Body Surface Area","unitOfMeasure":"meter square"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"55","upperLimit":"291","value":"59.1"},{"groupId":"BG001","lowerLimit":"57","upperLimit":"94","value":"61.8"},{"groupId":"BG002","lowerLimit":"34","upperLimit":"152","value":"45.8"},{"groupId":"BG003","lowerLimit":"46","upperLimit":"88","value":"80.4"},{"groupId":"BG004","lowerLimit":"13","upperLimit":"58","value":"38.4"},{"groupId":"BG005","lowerLimit":"44.62","upperLimit":"44.62","value":"44.62"},{"groupId":"BG006","lowerLimit":"21","upperLimit":"85","value":"35.2"},{"groupId":"BG007","lowerLimit":"19","upperLimit":"124","value":"56.9"},{"groupId":"BG008","lowerLimit":"12","upperLimit":"151","value":"42.7"},{"groupId":"BG009","lowerLimit":"61","upperLimit":"97","value":"71.9"},{"groupId":"BG010","lowerLimit":"46","upperLimit":"106","value":"76.1"},{"groupId":"BG011","lowerLimit":"12","upperLimit":"291","value":"57.4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"60"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time Since Primary Diagnosis to First Dose","unitOfMeasure":"months"}],"populationDescription":"Safety population included all participants who received at least 1 dose of ixazomib. A total of 60 participants participated in the study. There were 7 participants in Dose Escalation Cohort 6: Ixazomib 2.0 mg/m\\^2 arm group, 6 out of 7 participated in both phases of the study and were counted once in the expansion cohort."}